E
Enlaza Therapeutics is pioneering the field of covalent biologics. These novel classes of protein therapeutics deliver more efficacious and safer treatments for patients. The company’s proprietary War-Lock™ platform leverages leading synthetic biology technology for site-specific covalent coupling driven by drug binding. Enlaza is building a pipeline of first-in-class covalent biologics.
Investor insights
Funding rounds participated in
$100M sweet spot round size
Investor type
Privately Held
Basic info
Industry
Biotechnology Research
Sectors
Biotechnology Research
Funding rounds raised
Total raised
$100M
from 2 investors over 1 rounds
E
Enlaza Therapeutics raised $100M on May 30, 2024
Investors: J.P. Morgan Asset Management and + 8 Other investors